Analysis updated Oct 24, 2026 — scores and signals refreshed daily.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock research. Updated Oct 24, 2026. Q-Score 39/100 — Sell. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Sell (39.0) (grade D). 31 signals analyzed (26 differentiated alt-data).
StoQuant's analysis of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
CTNM stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-27 | $14.85 | $13.81 | $13.86 |
| 2026-08-04 | $16.70 | $15.31 | $15.90 |
| 2026-08-12 | $15.24 | $14.61 | $14.98 |
| 2026-08-20 | $16.29 | $15.68 | $16.02 |
| 2026-08-28 | $17.40 | $16.93 | $17.05 |
| 2026-09-08 | $16.95 | $15.88 | $15.94 |
| 2026-09-16 | $14.60 | $13.70 | $13.76 |
| 2026-09-24 | $12.74 | $11.40 | $12.49 |
| 2026-10-02 | $13.24 | $12.59 | $13.12 |
| 2026-10-12 | $11.54 | $8.43 | $8.57 |
| 2026-10-20 | $8.70 | $7.15 | $8.46 |
How Contineum Therapeutics, Inc. Class A Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $490M | — |
| IMMX | Immix Biopharma, Inc. | $486M | — |
| CBIO | Crescent Biopharma, Inc. | $521M | — |
| RLMD | Relmada Therapeutics, Inc. | $526M | — |
| GMRS | GMR Solutions Inc. | $533M | — |
View all Health Care stocks by valuation and signals →
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) scores Sell (39.0), and the composite conceals a 81-point disagreement between its dimensions. It is strongest on competitive moat at 91 and analyst consensus at 90, and weakest on technicals at 10. A stock can carry competitive moat that high while technicals sits at 10; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 91 |
| analyst consensus | 90 |
| AI Alpha (gem) | 75 |
| valuation | 65 |
| technicals | 10 |
StoQuant analyzes 31 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Contineum Therapeutics, Inc. Class A Common Stock (CTNM): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CTNM"><img src="https://stoquant.com/badge/CTNM.svg" alt="Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.